RajenJModyMDMS

Pediatric Hematology & Oncology • Ann Arbor, MI

Pediatric Solid Tumor Oncology

Ruth Heyn Professor of Pediatric Oncology, Director, Division of Pediatric Hematology/Oncology/ BMT, Director, Pediatric Developmental Therapeutics and Phase-I Program, Michigan Medicine

Join to view full profile

Dr. Mody is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mody's full profile

Already have an account?

Office
1500 E Medical Center Dr
BOX 5718
Ann Arbor, MI 48109
Phone+1 734-232-9335
Is this information wrong?

Education & Training

Scool Of Public Health, University Of MichiganM.S., Clinical Trial Design and Biostatistics, 2001 - 2003
University of Michigan Health SystemFellowship, Pediatric Hematology/Oncology, 1997 - 2000
SUNY Downstate Health Sciences UniversityResidency, Pediatrics, 1994 - 1997
N.H.L Municipal Medical CollegeClass of 1989

Certifications & Licensure

MI State Medical License 1997 - 2025
OH State Medical License 2006 - 2022
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma Start of enrollment: 2008 Apr 01
Completed
Phase 1
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
Active, not recruiting
Phase 1
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Aug 13
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Concurrent primary mediastinal germ cell tumor and acute myeloid leukemia: Case report of sustained remission and review of the literature.
Kristina Zalewski, Evan Cantor, Roland Chu, Greg Yanik, Laura Sedig, Rajen Mody> ;Pediatric Blood & Cancer. 2024 Apr 14
Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity res...
Haley Newman, Yimei Li, Yuan-Shung V Huang, Caitlin W Elgarten, Regina M Myers, Jenny Ruiz, Daniel J Zheng, Alison Barz Leahy, Catherine Aftandilian, Staci D Arnold, K...> ;Cancer Medicine. 2024 Apr 1
Primary myeloid sarcoma in an infant with an NRAS mutation.
Aarti Kamat, Valerie Opipari, Clayton Habiger, Rama Jasty, Rajen Mody, Laura Sedig> ;Pediatric Blood & Cancer. 2024 Mar 10
Family Recall of and Response to Germline Pathologic Variants Found on Paired Tumor-Germline Sequencing in Pediatric Oncology.
Michelle F Jacobs, Joshua W Goldman, Sarah Austin, Erika S Koeppe, Andrea M Murad, Carl J Koschmann, Arul M Chinnaiyan, Rajen J Mody> ;JCO Precision Oncology. 2024 Mar 1
"Better at home": Mixed methods report of intricacies in pediatric febrile neutropenia management.
Eleanor T Smeallie, Sung W Choi, Timothy C Guetterman, Charles N Nessle, Rajen Mody> ;Cancer Medicine. 2024 Mar 1
Further validation of poor prognosis for pediatric-rearranged leukemia and the need for rapid integration of targeted therapies for these patients.
Goldman, J., Mody, R.> ;Translational Pediatrics. 2024 Feb 29
A road map for the treatment of pediatric diffuse midline glioma.
Franson, A. (., Franson, A. (., Franson, A. (., Kilburn, L. B., Kilburn, L. B., Carl Koschmann, Wajd N Al-Holou, Marta M Alonso, Jamie Anastas, Pratiti Bandopadhayay, ...> ;Cancer Cell. 2024 Jan 8
Undifferentiated pleomorphic sarcoma of the pancreas with novel SARM1-NTRK1 gene fusion and associated pancreatitis, panniculitis, and polyarthritis syndrome.
Hoff, L., Wu, Y., Robinson, D., Bou-Maroun, L., Joshi, A., Bloom, D., Heider, A., Geiger, J., Mody, R., Rao, R.> ;Pediatric Blood & Cancer. 2024 Mar 1
2 citations
Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.
Holly J Roberts, Sunjong Ji, Alberto Picca, Marc Sanson, Mekka Garcia, Matija Snuderl, Ulrich Schüller, Thiébaud Picart, François Ducray, Adam L Green, Yoshiko Nakano,...> ;Acta Neuropathologica. 2023 Dec 1
23 citations
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Susan G Groshen, Judith G Villablanca, Kateryna Krytska, Lillian M Lai, Patricia T Achar...> ;Nature Medicine. 2023 May 1
Resolution of mandibular fibrous dysplasia following imatinib therapy in Noonan syndrome.
Joshua W Goldman, Sean Edwards, Rajen Mody, Rama Jasty-Rao> ;Pediatric Blood & Cancer. 2023 Jun 1
1 citations
Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia.
Elgarten, C., Otto, W., Shenton, L., Stein, M., Horowitz, J., Aftandilian, C., Arnold, S., Bona, K., Caywood, E., Collier, A., Gramatges, M., Henry, M., Lotterman, C.,...> ;Infection Control and Hospital Epidemiology. 2023 Feb 1
2 citations
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncolog...
Amy K Erbe, Mitch B Diccianni, Rajen Mody, Arlene Naranjo, Fan F Zhang, Jen Birstler, KyungMann Kim, Arika S Feils, Jung-Tung Hung, Wendy B London, Barry L Shulkin, Va...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
9 citations
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macro...
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D Weiss, Michelle Choe, Jennif...> ;Journal of Clinical Oncology. 2023 Jan 20
2 citations
Evaluation of the Association Between Congenital Cytomegalovirus Infection and Pediatric Acute Lymphoblastic Leukemia.
Jennifer M Geris, Mark R Schleiss, Anthony J Hooten, Erica Langer, Nelmary Hernandez-Alvarado, Michelle A Roesler, Jeannette Sample, Lindsay A Williams, David S Dicken...> ;JAMA Network Open. 2023 Jan 3
Impact of socio-behavioral measures implemented during the SARS-CoV-2 pandemic on the outcomes of febrile neutropenia episodes in pediatric cancer patients: a single c...
Charles Nathaniel Nessle, Tom Braun, Vineet Chopra, Sung Won Choi, Rajen Mody> ;Pediatric Hematology and Oncology. 2023 May 1
2 citations
Adolescent and parent perspectives on genomic sequencing to inform cancer care.
Laura K Sedig, Michelle F Jacobs, Rajen J Mody, Lan Q Le, Natalie J Bartnik, Michele C Gornick, Bailey Anderson, Arul M Chinnaiyan, J Scott Roberts> ;Pediatric Blood & Cancer. 2022 Sep 1
15 citations
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Evan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, Karthik Ravi, Chase Thomas, Rodrigo Cartaxo, Viveka Nand Yadav, Ramya Ravindran, Amy K Bruzek, Jack Wadden, Vishal J...> ;Neuro-Oncology. 2022 Aug 1
6 citations
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Ami V Desai, Mark A Applebaum, Theodore G Karrison, Akosua Oppong, Cindy Yuan, Katherine R Berg, Kyle MacQuarrie, Elizabeth Sokol, Anurekha G Hall, Navin Pinto, Ian Wo...> ;Cancer. 2022 Aug 1
Homozygous ATM mutation due to germline uniparental isodisomy in patient with T acute lymphoblastic leukemia and hepatosplenic T-cell lymphoma.
Michelle F Jacobs, Dan Robinson, Yi-Mi Wu, Valerie P Opipari, Rajen Mody> ;Cancer Genetics. 2022 Aug 1
2 citations
Internal evaluation of risk stratification tool using serial procalcitonin and clinical risk factors in pediatric febrile neutropenia: The non-interventional, single i...
C N Nessle, T Braun, S W Choi, R Mody> ;Pediatric Hematology and Oncology. 2023 Mar 1
4 citations
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Dana Messinger, Micah K Harris, Jessica R Cummings, Chase Thomas, Tao Yang, Stefan R Sweha, Rinette Woo, Robert Siddaway, Martin Burkert, Stefanie Stallard, Tingting Q...> ;Neuro-Oncology. 2023 Jan 5
19 citations
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c...
Pommert, L., Schafer, E., Malvar, J., Gossai, N., Florendo, E., Pulakanti, K., Heimbruch, K., Stelloh, C., Chi, Y., Sposto, R., Rao, S., Huynh, V., Brown, P., Chang, B...> ;American Journal of Hematology. 2022 May 1
5 citations
BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.
Lisa M Maurer, Jessica D Daley, Elina Mukherjee, Rosemarie E Venier, Claire M Julian, Nathanael G Bailey, Michelle F Jacobs, Chandan Kumar-Sinha, Haley Raphael, Nivith...> ;Cancer Research Communications. 2022 Apr 1
6 citations
Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia.
Kelly D. Getz, Julia E. Szymczak, Yimei Li, Rachel Madding, Yuan-Shung Huang, Catherine Aftandilian, Staci D. Arnold, Kira Bona, Emi Caywood, Anderson B. Collier, M. M...> ;JAMA Network Open. 2021 Oct 1
Join now to see all

Lectures

Where Are We Now?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblasto...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Pediatric Melanoma and Aggressive Spitz Tumors: A Retrospective Diagnostic, Exposure and Outcome AnalysisJanuary 2018

Press Mentions

A Novel ATXN1-DUX4 Fusion Expands the Spectrum of ‘CIC-Rearranged Sarcoma’ of the CNS to Include Non-CIC AlterationsFebruary 7th, 2021
Probing Why Cancer Outcomes Are Worse for Minority KidsJune 11th, 2018
Pediatric Melanoma and Aggressive Spitz Tumors: A Retrospective Diagnostic, Exposure and Outcome AnalysisJanuary 3rd, 2018
Join now to see all